Discovery of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG, for the treatment of cancer. | 2017 ASCO Annual Meeting Abstracts
3074 Discovery of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG, for the treatment of cancer. Spencer Liang, Ofer Levy, Sudipto Ganguly, Maya Kotturi, Ilan Vaknin, Liat Dassa, Meir Azulay, Zoya Alteber, Kyle Hansen, Chris
The share price is still ludicrously underpriced.
Compugen Ltd. (CGEN) Given a $14.00 Price Target by FBR & Co Analysts Posted by Michael Walen on May 19th, 2017 // No Comments Compugen logoCompugen Ltd. (NASDAQ:CGEN) has been given a $14.00 price target by research analysts at FBR & Co in a research note issued to investors on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. FBR & Co’s price objective would indicate a potential upside of 225.58% from the company’s current price. Compugen (NASDAQ:CGEN) traded up 2.33% during trading on Friday, hitting $4.40. The stock had a trading volume of 36,912 shares. The company’s 50-day moving average is $4.08 and its 200 day moving average is $4.90. Compugen has a 52 week low of $3.60 and a 52 week high of $7.57. The firm’s market cap is $224.98 million.
Very interesting bringing Michel Preminger PHD on board with her background
Renaissance Technologies LLC Boosts Stake in Compugen Ltd. (CGEN)
Renaissance Technologies LLC raised its position in Compugen Ltd. (NASDAQ:CGEN) by 15.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 534,900 shares of the biotech
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.3 In other words, the correlation coefficient of the other stock
The Good, the Bad and the Ugly
THE GOOD: In the conference call Anat opined that PVRIG could prove an important checkpoint, and wasn’t sure if it’s “better” than PD1. Moreover, it seems likely, I think, that COM701 and COM902 will need to be licensed together, given their symbiosis. This is exciting. Just consider if there were only one company in the world to discover the PD1 checkpoint and optimise an MAB against it… what would that company be worth? THE BAD: Now despite the fact that CGEN share price has risen some 15% since the call, we’re still languishing near a 4-year low. Hardly a cause for celebration. Martin said that CGEN would make an exception in this call and provide details of commercialization efforts. Why should the share price have to plumb catastrophic levels in order for management to wake up and provide relevant information to the owners of the company, i.e. the shareholders? It’s absurd. THE UGLY: At the end of the conference call we were told that there were no further questions. False. There were. These were questions, called in immediately when lines were opened, from L-T shareholders that management apparently decided not to accept. Perhaps the CEO and CFO would care to explain why. It would be wise to recall that many L-T shareholders have stuck with the company, through tough times, for longer than Anat and Krashin have been employed. For us to be treated as an unpleasant burden is distasteful.
SBH - Thanks for sharing the article last week - here's a supportive paragraph:
Stage 1 tumors already showed a rich gathering of suppressive macrophages and T cells, as well as the depletion of natural killer (NK) cells that help activate the immune system. These tumors are typically removed surgically, and while they usually have a good prognosis, 25% of patients relapse.
"In this study we identified many immune suppressive changes that could be targeted to induce an immune attack and an immune memory response against these small tumors, and we are currently testing these questions in animal models," Dr. Merad says. "We are very excited about these results because we believe that targeting tumor cells at this small stage has much higher chances to get rid of all tumor cells than if we unleashed an immune attack in larger tumors where risk of tumor cell dissemination is higher."
13-F Filings Today ... and our Number #1 shareholder Bought 1mm + additional shares for 4mm+ ....like i said .. not them selling
Some person or entity likes CGEN today. Currently up on a lot of volume.
As we await tomorrow’s conference call, I thought some here might be interested in this article featuring the newest member of Compugen’s Scientific Advisory Board, Dr. Miriam Merad, (Director of the Precision Immunology Institute and the Co-Leader of the Cancer Immunology Immunotherapy program at The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai. )
Immunotherapy Advanced by Immune Cell Studies of Lung and Kidney Cancers | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN
Two independent research teams begin mapping connections among the thousands of immune cells surrounding human tumors
Capitulation and Optimists Over the last few weeks the volumes traded on a daily basis have been well below average with capitulation by those unwilling to suffer further losses and with no remaining faith in either management or the commercial value of the science. I like many long term holders can remember meaningful capitulation when the shares dipped below 1$ but equally can recall it's recovery to above 12$. Are the prospects any better now than a few years back we ask ourselves and being optimistic we answer "Yes". There are real concerns, cash burn, Bayer collaboration, competence of management, competition to name but a few and unless we have some answers at next week's Con.Call we believers may be tempted to join those selling. The call should not be littered with false promises and comments made in the past but reflect realism and clarity. It will be an interesting and somewhat critical call particularly for those who recognise the scientific excellence but are frustrated by the commercial incompetence of the Board!!
Think I've had enough of Compugen. If I had money for all the conferences they've presented at I'd be fine, but that's not how this game is scored. They seem unable to deliver.
Is the Bayer collaboration over? Is there any other potential collaborator other than Johns Hopkins? If not, despite dozens of promising newly discovered checkpoint inhibitors, this will languish for years IMO. Someone (I'll try myself) but I work for a living, needs to ask this question next week. If nothing comes out of this conference call or ASCO, I'm out and will take my licks with my 13,000 shares I was sure would be 10 by now!
I entered a limit order to buy 2,000 CGEN @ 3.80 this morning. I got 100 @ 10:48AM, 150 @ 3:31PM, 10 @ 3:33PM. Starting @ 3:34PM and ending @ 3:59PM, in 26 separate trades (a minute or so apart) ranging from 4 to 8 shares each (almost all 5 or 6) I got a total of 142 shares. Something unusual is going on in this situation. I have seen this kind of thing a few times over the years and always wonder why this happens. Any ideas?
Check point inhibition/ targeting is among the hottest areas in oncology. IMO we'll ultimately be closer to 7-8 than 3-4 within the next year if you can wait that long.
this board must be in shock watching it melt - well , no management Buying , no board changes - we go Lower and all of the long term shareholders debate who will see 1st
Up @ 4.25 down below 4 we trade last few days- maybe Bayer comes through before conf call...?? it has been 1 year 4 months since the took over and around 8 months when Anat was saying they are in IND enabling - terrible communications
Conspiracy Theory Make no mistake,the value of Cgen is well above it's current market value and recent decline is partly due to the small speculators who delight in "day trading". However this may suit the purpose of those who may seek to buy the company and it's well documented pipeline. Why consider a collaboration when they might be able to buy all at a "knock down" price. Perhaps this is fanciful or wishful thinking but it is not beyond the bounds of possibility. Conversely it may be that this small Israeli company is now behind the "ape ball", about to be dumped by Bayer and as a consequence may continue to haemorrhage and be at the mercy of the financial vultures.